<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04680702</url>
  </required_header>
  <id_info>
    <org_study_id>siMS SCORE</org_study_id>
    <nct_id>NCT04680702</nct_id>
  </id_info>
  <brief_title>Metabolic Syndrome and Sims Score</brief_title>
  <official_title>Evaluation Of siMS Score As Amarker Of Metabolic Syndrome In Children With Simple Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SiMSscore was used as a simple and accurate method for Quantifying Metabolic Syndrome in&#xD;
      adults , Developed siMS score was calculated using formula: siMS score = 2*Waist/Height +&#xD;
      Gly/5.6 + Tg/1.7 + TAsystolic/130-HDL/1.02 or 1.28 (for male or female subjects,&#xD;
      respectively),However studies on siMSscor in pediatric was done .&#xD;
&#xD;
      PsiMSscore(pediatric sims score) calculated using formula: (2xWaist/Height) +&#xD;
      (Glucose(mmol/l)/5.6) + (triglycerides(mmol/l)/1.7) + (Systolic&#xD;
      BP/130)-(HDL(mmol/l)/1.02(Soldatovic etal;2016).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metabolic Syndrome (MetS) is defined as a cluster of cardio metabolic risk factors that&#xD;
      include central obesity low levels of high-density lipoprotein-cholesterol (HDL-C),&#xD;
      hypertriglyceridemia, hypertension, and hyperglycaemia. Metabolic changes in childhood track&#xD;
      into adulthood, predisposing these individuals to type 2 diabetes, and cardiovascular&#xD;
      diseases.&#xD;
&#xD;
      The underlying prevalence of MetS in adolescents depends on the set of MetScri:eria used,&#xD;
      with overall ranges in the US from 1.2%-9.8% using modified ATP-III criteria (Adult Treatment&#xD;
      PanelII) to 4.5%-8.4% using the IDF adolescent criteria . Assessments among school-aged&#xD;
      children and early adolescents islower (0.2%-1.2%) which is likely because of the strong&#xD;
      effects of puberty on insulin resistance.&#xD;
&#xD;
      There is no consensus regarding the diagnosis of metabolic syndrome in children and&#xD;
      adolescents. It is evident that each component of the syndrome must be identified as early as&#xD;
      possible in order to prevent definitive lesion Pediatric and adolescent metabolic syndrome&#xD;
      (MetS) criteria adapted from the National Cholesterol Education Program Adult Treatment Panel&#xD;
      III (ATP lll),&#xD;
&#xD;
        1. Central Obesity (WC): WC ≥ 90th percentile .&#xD;
&#xD;
        2. High BP (mmHg) : Systolic or diastolic DBP≥ 90% for age, sex, height&#xD;
&#xD;
        3. High Triglycerides (mg/dL) : TG ≥ 110 mg/dL (≥1.24 mmol/L) .&#xD;
&#xD;
        4. HDL ≤ 40 mg/dL(&lt;1.03 mmol/L).&#xD;
&#xD;
        5. High Fasting Glucose :≥100 mg/dL (5.6 mmol/L) or known T2DM. Individuals need to have at&#xD;
           least three abnormalities in MetS components to be classified as havingMetS SiMSscore&#xD;
           was used as a simple and accurate method for Quantifying Metabolic Syndrome in adults ,&#xD;
           Developed siMS score was calculated using formula: siMS score = 2*Waist/Height + Gly/5.6&#xD;
           + Tg/1.7 + TAsystolic/130-HDL/1.02 or 1.28 (for male or female subjects,&#xD;
           respectively),However studies on siMSscor in pediatric was done .&#xD;
&#xD;
      PsiMSscore(pediatric sims score) calculated using formula: (2xWaist/Height) +&#xD;
      (Glucose(mmol/l)/5.6) + (triglycerides(mmol/l)/1.7) + (Systolic BP/130)-(HDL(mmol/l)/1.02&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 29, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sims score as screening method of metabolic syndrome in pediatric in one year</measure>
    <time_frame>sims score as screening method of metabolic syndrome in pediatric in one year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Metabolic Syndrome , Sims Score and Pediatrics</condition>
  <arm_group>
    <arm_group_label>Metabolic Syndrome and Sims Score</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Sims Score</intervention_name>
    <description>Evaluation Of siMS Score As Amarker Of Metabolic Syndrome In Children With Simple Obesity</description>
    <arm_group_label>Metabolic Syndrome and Sims Score</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All obese patients aged from 7 to 17 years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  All obesechildren&#xD;
&#xD;
               -  With endocrial and syndromatic obesity, (Endocrinal disease as hypothyroidism and&#xD;
                  Cushing's syndrome etc, syndromic obesity asPrader-Willi syndrome&#xD;
                  ,Alstrom-Hallgren syndrome, Bardet-Biedl syndrome,&#xD;
                  Beckwith-Wiedemansyndrome,etc…….)&#xD;
&#xD;
               -  Children on medications that affect lipid profile that include (β-Blockers&#xD;
                  ,Amiodarone ,Loop diuretics, Thiazide diuretics (high dose) ,Sodium-glucose&#xD;
                  co-transporter 2 (SGLT2) inhibitors ,Steroid Hormones/Anabolic Steroids,&#xD;
                  Antiviral Therapy ,Immunosuppressants ,Centrally Acting Medications as&#xD;
                  Anticonvulsants).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>noha gamal, professor</last_name>
    <role>Study Director</role>
    <affiliation>Director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>basma sayed, master</last_name>
    <phone>01010604622</phone>
    <email>basmasayedib@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assuit Univesrity</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 18, 2020</study_first_submitted>
  <study_first_submitted_qc>December 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>December 28, 2020</last_update_submitted>
  <last_update_submitted_qc>December 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>BASMA SAYED</investigator_full_name>
    <investigator_title>assistant lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

